17 As such, icodec treatment may reduce delays in insulin initiation and may improve treatment adherence and convenience, given that it would reduce basal insulin injections from at least 365 per year to only 52 per year. Another once-weekly insulin, efsitora alfa, is also in clinical ...
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20(5):1202–12. Article CAS Google Scholar Seino Y, Terauchi Y, Osonoi T, et al. Safety and ...
Diabetic MedicineGrunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled...
ONWARDS 1 was a phase 3a, 78-week, open-label efficacy and safety treat-to-target trial comparing once-weekly insulin icodec with once-daily basal insulin glargine U100, both in combination with non-insulin anti-diabetic treatments, in 984 insulin-naïve adults with T2D. Investi...
However, its current formulation requires twice daily subcutaneous injections and does not provide continuous GLP-1R activation. Therefore, a long-acting release form of exenatide has been developed for use as a once-weekly injection, providing for convenient administration and continuous GLP-1R ...
Therefore, we aimed to compare the effectiveness of dulaglutide versus liraglutide and exenatide once weekly (exeOW) in type 2 diabetic (T2D) patients under routine care.关键词:GLP-1 Effectiveness HbA1c Propensity score matching Observational Real-word ...
without T2DM.31 Clinical Practice Guidelines suggest that a daily reduction in energy intake of 2.6 MJ will predict a weight loss of about 0.5 kg weekly (assuming no change in EE).32 This study is the first to investigate the effects of liraglutide on 24-h EE in obese non-diabetic ...
Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy 来自 学术范 喜欢 0 阅读量: 28 作者: E Albright 摘要: Diabetes Care. 2004 Feb;27(2):632-3. Clinical Trial; Comparative Study...
In preclinical in vivo pharmacology studies using streptozotocin (STZ)-treated diabetic rats, a statistically significant decrease in blood glucose compared to vehicle-treated animals was seen 24 hours post-injection and persisted through 336 hours post-injection following a single subcutaneous ...
Tsuji T, Inoue M, Yoshida Y, Fujita T, Kaino Y and Kohno T: Therapeutic approach for type 1 diabetes mellitus using the novel immunomodulator FTY720 (fingolimod) in combination with once‑daily injection of insulin glargine in non‑obese diabetic mice. J Diabetes Investig 3: 132‑137, ...